Argos Therapeutics (ARGS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Argos Therapeutics (ARGS) Misses Q1 EPS by 1c
May 12, 2016 4:06 PM EDT
- Entered into Equity Financing for Up to $60 million -
- Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring Committee -
- Dr. Lee F. Allen joined as Chief Medical Officer -
- Investigator-initiated Phase 2 Study of AGS-003 in Non-Small Cell Lung Cancer Opened for Enrollment -
- Conference Call and Webcast Today, May 12th, at 4:30 p.m. ET -
DURHAM, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Argos... More
May 11, 2016 4:06 PM EDT
DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company will participate in the World Stem Cells and Regenerative Medicine Congress to be held May 18-20, 2016 at the Business Design Centre in London.
Fred Miesowicz, Ph.D., special advisor and former chief operating officer of Argos, will join a panel titled, Thinking beyond efficacy considerations for... More
